Neuropsychiatric Symptoms of Urbach-Wiethe Disease

Richard P. Conti^1, and Jacqueline M. Arnone²

¹School of Psychology, Kean University, Union, NJ, USA

²Department of Nursing, Kean University, Union, NJ, USA

Cite this paper:
Richard P. Conti and Jacqueline M. Arnone. Neuropsychiatric Symptoms of Urbach-Wiethe Disease. International Journal of Clinical and Experimental Neurology. 2015; 3(2):45-50. doi: 10.12691/ijcen-3-2-3

Abstract

Urbach–Wiethe (or lipoid proteinosis) disease (UWD) is a rare autosomal recessive disorder characterized by dermatological, psychiatric, and neurological symptoms. Presentation occurs during childhood, but can be observed from birth. While benign, the disease is progressive and chronic with no known cure. Treatment modalities are palliative for symptoms. The extant literature consists mainly of anecdotal reports and case studies that are limited by small sample sizes and paucity of controlled studies. Incidence and prevalence rates are unknown. There are less than 500 documented cases reported worldwide, and of those, less than 50 cases demonstrate neurological and neuropsychiatric conditions. Worldwide occurrence of the disease is documented, with the largest cohort living in a remote area of South Africa. The affected individuals are mainly Caucasian, born to consanguineous parents, and from Dutch or German heritage. Patients affected have been reported in China, Pakistan and Iran. Current and earlier studies focus primarily on the most visible signs of disease, dystonia and dermatological symptoms, while other studies have reported calcification in the amygdala, hippocampus, parahippocampal gyrus, and the striatum. While central nervous system involvement can lead to a wide range of clinical manifestations such as epilepsy and neuropsychiatric symptoms, there is not a consensus of reported cases with amygdala calcifications accompanied by neurological symptoms. Quantitative research is warranted to further identify the role and relationship between amygdala calcification and neurologic and neuropsychiatric symptoms, while qualitative research will afford insights into the lived experience of individuals and families living with UWD.

Keywords:
Urbach-Wiethe disease lipid proteinosis neurological neuropsychiatric amygdala

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Siebert M., Markowitsch H.J., and Bartel P. “Amygdala, affect and cognition: evidence from 10 patients with Urbach-Wiethe disease,” Brain, 2003; 126: 2627-2637.
[2]	Thornton H.B., Nel D., Thornton D., van Honk J., Baker G.A., and Stein D.J. “The neuropsychiatry and neuropsychology of lipoid proteinosis,” J Neuropsychiatry Clin Neurosci, 2008; 20: 86-92.
[3]	Goncalves F.G., de Melo M.B., de L. Matos V., Barra F.R., and Figueroa R.E. “Amygdalae and striatum calcification in lipoid proteinosis,” Am J Neuroradiol, 2010; 31: 88-90.
[4]	Appenzeller S., Chaloult E., Velho P., et al. “Amygdalae calcifications associated with disease duration in lipoid proteinosis.” J Neuroimag, 2006; 16: 154-156.
[5]	Aziz M.T., Mandour M.A., El-Ghazzawi I.F., Belal A.-E.-A., and Talaat A.M. “Urbach-Wiethe disease in ORL practice (A clinical and histochemical study of the laryngeal lesions),” J Laryngol Otol, 1980; 94: 1309-1319.
[6]	Yakout Y.M., Elwany S., Abdel-Kreem A., and Seif S.A. “Radiological finding in lipoid proteinosis,” J Laryngol Otol, 1985; 99: 259-265.
[7]	Urbach E., and Wiethe C. “Lipoidosis cutis et mucosa,” Virchows Archiv Pathol, 1929; 27: 286-319.
[8]	Hamada T., McLean W.H.I., Ramsay M., Ashton G.H.S., Nanda A., Jenkins T., Edelstein I., South A.P., Bleck O., Wessagowit V., Mallipeddi R., and Orchard G.E. “G. Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1),” Hum Molec. Genet, 2002; 11: 833-840.
[9]	Hamada T., Wessagowit V., South A.P., Ashton G.H.S., Chan I., Oyama N., Siriwattana A., and McGrath J.A. “Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correllation,” J Invest Dermatol, 2003; 120: 345-350.
[10]	Kachewar, S.G., and Kulkarni, D.S. “A novel association of the additional intracranial calcification in lipid proteinosis: A case report.” J Clin and Diag Res, 2012; 9: 1579-1581.
[11]	Morgan B., Terburg D., Thornton H.B., Stein D.J., and van Honk J. “Paradoxical facilitation of working memory after basolateral amygdala damage,” Plos One, 2012; 7(6): e38116.
[12]	Emsley R.A., and Paster L. “Lipoid proteinosis presenting with neuropsychiatric manifestations,” J Neurol Neurosurg Psychiatry, 1985; 48:1290-1292.
[13]	Holme S.A., Lenane P., and Krafchik B.R. “What syndrome is this? Urbach-Weithe syndrome (Lipoid proteinosis),” Pediatr Dermatol, 2005; 22(3): 266-267.
[14]	Kachewar S., Singh B.H., Sasane A.G., and Bhadane S. “Full blown case of lipoid proteinosis,” Med J Armed Forces of India, 2011; 67: 90-91.
[15]	Nanda A., Alsaleh Q.A., Al-Sabah H., Ali A.M., and Anim J.T. “Lipoid Proteinosis: Report of four siblings and brief review of the literature,” Pediatr Dermatol, 2001; 18(1): 21-26.
[16]	Sainani M.P., Muralidhar R., Parthiban K., and Vijayalakshmi P. “Lipoid proteinosis of Urbach and Wiethe: A case report,” Int Opthalmol, 2011; 31: 141-143.
[17]	Hofer P.A. “Urbach-Wiethe disease (lipoglycoproteinosis; lipoid proteinosis; hyalinoses cutis et mucosae). A review,” Acta Dermato Venereologica Supplementum, 1973; 53: 1-52.
[18]	Toosi S., and Ehsani A.H. “Treatment of lipoid proteinosis with acitretin: A case report,” J Eur Acad Dermatol, 2009; 23: 482-483.
[19]	Wong C.K., and Lin C.S. “Remarkable response of lipid proteinosis to oral dimethylsulphoxide,” Brit J Dermatol, 1988; 119: 541-544.
[20]	Zhang R., Liu Y., Xue Y., Wang Y., Wang X., Shi S., Cai T., and Wang Q. “Treatment of lipoid proteinosis due to the p.C220G mutation in ECM1, a major allele in Chinese patients,” J Transl Med, 2014; 12(85).
[21]	Hamann S.B., Ely T.D., Hoffman J.M., and Kilts C.D. “Ecstasy and Agony: Activation of the human amygdala in positive and negative emotion,” Psychol Sci, 2002; 13(2): 135-141.
[22]	Markowitsch, H.J., and Staniloiu A. “Amygdala in action: Relaying biological and social significance to autobiographical memory,” Neuropsychologia, 2011; 49 (4): 718-733.
[23]	Terburg D., Morgan B. E., Montoya E. R., Hooge I.T., Thornton H.B., Hariri A.R., ... and van Honk J. “Hypervigilance for fear after basolateral amygdala damage in humans,” Transl Psychiatry, 2012; 2e115.
[24]	Bach, D. R., Talmi, D., Hurlemann, R., Patin, A., and Dolan, R. J. “Automatic relevance detection in the absence of a functional amygdala,” Neuropsychologia, 2011; 49(5): 1302-1305.
[25]	Yang, T. T., Menon, V., Eliez, S., Blasey, C., White, C. D., Reid, A. J.... and Reiss, A. L. “Amygdalar activation associated with positive and negative facial expressions,” Neuroreport, 2002; 13(14): 1737-1741.
[26]	Tranel, D., Gullickson, G., Koch, M., and Adolphs, R. “Altered experience of emotion following bilateral amygdala damage,” Cogn Neuropsychiatry, 2006; 11(3): 219-232.
[27]	Chan I., Liu L., Hamada T., Sethuraman G., and McGrath J.A. “The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein,” Exp Dermatol, 2007; 16: 881-890.
[28]	Boudouresque J., Cosset A., and Sayag J. “Maladie d’Urbach-Whiethe: Crises temporales avec phenomenes extatiques et calcification des deux lobes temporaux,” Bull Acad Med Paris, 1972; 156: 416-442.
[29]	Claeys K.G., Claes L.R.F., Van Goethem J.W.M., et al. “Epilepsy and migraine in a patient with Urbach–Wiethe disease,” Seizure, 2007; 16: 465-468.
[30]	Omrani H.G., Tajdini M., Ghelichnia B., et al. “Should we think of Urbach–Wiethe disease in refractory epilepsy? Case report and review of the literature,” J Neurol Sci, 2012; 320: 149-152.
[31]	Matthies S., Rüsch N., Weber M., et al. “Small amygdala–high aggression? The role of the amygdala in modulating aggression in healthy subjects,” World J Biol Psychiatry, 2012; 13(1): 75-78.
[32]	Newton F.H., Rosenberg R.N., Lampert P.W., and O'Brien J.S. “Neurologic involvement in Urbach‐Wiethe's disease (lipoid proteinosis) A clinical, ultrastructural, and chemical study,” Neurol, 1971; (12), 1205-1213.
[33]	Lupo I., Cefalu A.B., Bongiorno M.R., et al. “A novel mutation of the extracellular matrix protein 1 gene (ECM1) in a patient with lipoid proteinosis (Urbach-Wiethe disease) from Sicily,” Brit J Dermatol, 2005; 153(5): 1019-1022.
[34]	Kleinert R., Cervos-Navarro J., Kleinert G., et al. “Predominantly cerebral manifestation in Urbach-Wiethe's syndrome (lipoid proteinosis cutis et mucosae): A clinical and pathomorphological study,” Clin Neuropathol, 1986; 6(1): 43-45.
[35]	Adolphs R., Tranel D., Damasio H., and Damasio A. “Impaired recognition of emotion in facial expression following bilateral damage to the human amygdala,” Nature, 1994; 372: 669-672.
[36]	Adolphs R., Tranel D., Damasio H., and Damasio A.R. “Fear and the human amygdala,” J Neurosci, 1995; 15: 5879-5891.
[37]	Paul L.K., Corsello C., Tranel D., and Adolphs R. “Does bilateral damage to the human amygdala produce autistic symptoms?,” J Neurodev Disord, 2010; 2(3): 165-173.
[38]	Adolphs, R., and Tranel, D. “Impaired judgments of sadness but not happiness following bilateral amygdala damage,” J Cogn Neurosci, 2004; 16(3): 453-462.
[39]	Adolphs R., Gosselin F., Buchanan T.W., Tranel D., Schyns P.G, and Damasio A. “A mechanism for impaired fear recognition after amygdala damage,” Nature, 2005; 433: 68-72.
[40]	Adolphs R., Spezio M.L., Parlier M., and Piven J. “Distinct face-processing strategies in parents of autistic children,” Curr Biol, 2008; 18: 1090-1093.
[41]	Böhme M., and Wahlgren C.F. “Lipoid proteinosis in three children,” Acta Paediatrica, 1996; 85(8): 1003-1005.
[42]	Bahadir S., Cobanoglu U., Kapicioglu Z., et al. “Lipoid proteinosis: A case with ophthalmological and psychiatric findings,” J Dermatol, 2006; 33(3): 215-218.
[43]	Salih M.A., Abu-Amero K.K., Alrasheed S., et al. “Molecular and neurological characterizations of three Saudi families with lipoid proteinosis,” BMC Med Genet, 2011; 12(3).
[44]	Markowitsch H.J., Calabrese P., Würker M., Durwen H.F., et al. “The amygdala's contribution to memory-a study on two patients with Urbach-Wiethe disease,” Neuroreport, 1994; 5(11): 1349-1352.
[45]	Cahill L., Haier R.J., Fallon J., Alkire M.T., Tang C., Keator D., et al. “Amygdala activity at encoding correlated with long‐term, free recall of emotional information,” Proc Natl Acad Sci USA, 1996; 93(15): 8016-8021.
[46]	Adolphs R, Cahill L., Schul R., and Babinsky R. “Impaired declarative memory for emotional material following bilateral amygdala damage in humans,” Learn Memory, 1997; 4(3): 291-300.
[47]	Hurlemann R., Wagner M., Hawellek B., et al. “Amygdala control of emotion-induced forgetting and remembering: Evidence from Urbach-Wiethe disease,” Neuropsychologia. 2007; 45(5): 877-884.
[48]	Claeys K.G., Claes L.R.F., Van Goethem J.W.M., et al. “Epilepsy and migraine in a patient with Urbach–Wiethe disease,” Seizure, 2007; 16(5): 465-468.
[49]	Wiest G., Lehner-Baumgartner E., and Baumgartner C. “Panic attacks in an individual with bilateral selective lesions of the amygdala,” Arch Neurol, 2006; 63(12): 1798-1801.
[50]	Brand M., Grabenhorst F., Starcke K., Vandekerckhove M.M., and Markowitsch H.J. “Role of the amygdala in decisions under ambiguity and decisions under risk: evidence from patients with Urbach-Wiethe disease,” Neuropsychologia, 2007; 45(6): 1305-1317.
[51]	Becker, B., Mihov, Y., Scheele, D., Kendrick, K. M., Feinstein, J. S., Matusch, A.,... and Hurlemann, R. “Fear processing and social networking in the absence of a functional amygdala,” Biol Psychiatry, 2012; 72(1): 70-77.